Search

K. Clinton Cary, MD, MPH

Assistant Professor, Department of Urology, Indiana University School of Medicine
Research Scientist, Indiana University Center for Health Services and Outcomes Research
Research Scientist, William M. Tierney Center for Health Services Research, Regenstrief Institute, Inc.

   Dr. Cary is a research scientist in Regenstrief Institute's William M. Tierney Center for Health Services Research and Assistant Professor in the Department of Urology at Indiana University School of Medicine. Dr. Cary provides direct medical and surgical care for general urology and urologic oncology patients. His research efforts are focused on improving the health of patients with urologic cancers through health services and outcomes research in testis, bladder, and prostate cancer. He has an active pilot study in progress to assess utilization rates of single dose intravesical chemotherapy in patients with non-muscle invasive bladder cancer in a population-based environment.

 

   Dr. Cary serves on the Scientific Review Committee at the Indiana University Simon Cancer Center, the Medical Staff Oversight and Credentials Committees at Eskenazi Health, and the Cancer Registry Advisory Board at the Indiana State Department of Health.

Dr. Cary is licensed by the Medical Licensing Board of the State of Indiana and a staff physician at Indiana University Health.

Indiana University Health Profile

 

CLINICAL INTERESTS

Urologic Oncology, including:
    Testis Cancer
    Bladder Cancer
    Prostate Cancer
    Robotic Surgery in Urologic Cancers
    Reconstructive Surgery

 

HOSPITALS & AFFILIATIONS

Physician Group:  
     IU Health Physicians  
Hospital Privileges:  
     IU Health Methodist/IU Health University  

 

EDUCATION

Masters Degree      University of California Berkeley
School of Medicine      University of Tennessee Health Science Center
Internship      Indiana University
Residency      Indiana University
Fellowship      University of California, San Francisco

Active Projects

I.  Regenstrief Institute, Inc. (2015)

“Assessing Utilization of Intravesical Chemotherapy in Bladder Cancer (PI)

Pilot study to identify rates of utilization among physicians of single dose intravesical chemotherapy, an evidence-based treatment following transurethral tumor resection to reduce tumor recurrence and potentially ease the economic burden of cancer surveillance.

 

II. IU Simon Cancer Center (2014-2016)

"Genomic Markers in Transitional Cell Cancer of the Bladder, Renal Pelvis and Ureter: Sample Acquisition for Methods Development and Discovery". Genomic Health. (PI)  


Selected Publications                               |                            Go To PubMed List >>
  1. Chovanec M, Hanna N, Cary KC, Einhorn L, Albany C. Management of stage I testicular germ cell tumours. Nat Rev Urol. 2016 Nov;13(11):663-673. doi:10.1038/nrurol.2016.164. PubMed PMID: 27618772.

  2. Kaimakliotis HZ, Monn MF, Cho JS, Pedrosa JA, Hahn NM, Albany C, Gellhaus PT, Cary KC, Masterson TA, Foster RS, Bihrle R, Cheng L, Koch MO. Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology. Future Oncol. 2016 Aug;12(15):1795-804. doi: 10.2217/fon-2016-0056. PubMed PMID: 27255805.

  3. Monn MF, Kaimakliotis HZ, Cary KC, Bihrle R, Pedrosa JA, Masterson TA, Foster RS, Gardner TA, Cheng L, Koch MO. The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? BJU Int. 2015 Aug;116(2):236-40. doi: 10.1111/bju.12877. PubMed PMID: 25060358.

  4. Bahler CD, Cary KC, Garg S, DeRoo EM, Tabib CH, Kansal JK, Monn MF, Flack CK, Masterson TA, Sandrasegaran MK, Foster RS, Sundaram CP. Differentiating reconstructive techniques in partial nephrectomy: a propensity score analysis. Can J Urol. 2015 Jun;22(3):7788-96. PubMed PMID: 26068626.

  5. Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR; NIDDK Urologic Diseases in America Project. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate Cancer Prostatic Dis. 2015 Jun;18(2):149-54. doi: 10.1038/pcan.2015.3. PubMed PMID: 25667110; PubMed Central PMCID: PMC4430397.

  6. Cary KC, Pedrosa JA, Kaimakliotis HZ, Masterson TA, Einhorn LH, Foster RS. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors. J Urol. 2015 Feb;193(2):507-12. doi: 10.1016/j.juro.2014.09.090. PubMed PMID: 25254937.

  7. Yang DY, Monn MF, Kaimakliotis HZ, Cary KC, Cheng L, Koch MO. Oncologic and quality-of-life outcomes with wide resection in robot-assisted laparoscopic radical prostatectomy. Urol Oncol. 2015 Feb;33(2):70.e9-14. doi: 10.1016/j.urolonc.2014.07.003. PubMed PMID: 25240762.

  8. Pedrosa JA, Koch MO, Kaimakliotis HZ, Monn MF, Masterson TA, Rice KR, Cary KC, Foster RS, Bihrle R, Cheng L. Three-tiered nodal classification system for bladder cancer: a new proposal. Future Oncol. 2015;11(3):399-408. doi:10.2217/fon.14.267. PubMed PMID: 25675122.

  9. Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, Koch MO. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol. 2015 Jan;33(1):18.e15-20. doi: 10.1016/j.urolonc.2014.10.001. PubMed PMID: 25459358.

  10. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec;114(6b):E18-24. doi:10.1111/bju.12554. PubMed PMID: 24712895.

 


IU CHSOR | 1101 West Tenth Street, 2nd Floor | Campus Address: Regenstrief Building (RF2) | Indianapolis, Indiana 46202-4800 | Ph: 317.274.9026 | Fax: 317.274.9304